LSPR Nanosensor for Simplified Clinical Assays

描述(由申请人提供)：护理点(POC)测试(也称为就近患者、床边或额外的实验室测试)可以改善医疗保健的临床结果。这些改进包括更快的决策，更早的治疗开始，更好的坚持治疗，减少并发症的发生率，更快地优化治疗，降低再次住院率，以及更好的患者满意度。此外，还可以带来额外的运营和经济效益。这些潜在的好处为POC测试创造了一个日益增长的市场，这种测试可以帮助诊断和治疗各种医疗疾病和状况。为了实现有效和准确的POC测试，测试方法必须易于使用，提供准确的答案，在时间尺度上提供结果，需要手持或小型台式仪器，并且需要对测试操作人员进行最低限度的培训。目前寻求满足POC测试需要的方法的一个限制是所使用的仪器的成本和复杂性，以及正确执行分析程序所需的培训。为了克服这一限制，智能光学系统公司建议将一种简单的无标签临床检测系统扩展到广泛的POC应用，并在以后使用相同的技术来解决高通量筛查应用。在第一阶段工作中开发的雌二醇法，基于对一组银纳米板上局部表面等离子体共振(LSPR)的观察，将扩展到开发用于卵巢癌早期诊断的临床分析小组。这些专家小组将同时检测用于乳腺癌预后和生育治疗的几个指标。这些都是医学上重要的、商业上有吸引力的应用，将使基本的LSPR分析系统开发成商业产品。将为化验化学、一次性化验底物和用于所有化验操作的手持式仪器开发设计。这些产品的商业化有望导致检测技术的进一步扩展，并作为广泛POC测试的平台。检测系统还将扩大，以满足高通量筛查应用。预计这两种类型的分析在时间和成本上都会有相当大的节省。公共卫生相关性：现在可以在给予病人护理的地点在短时间内进行许多临床医学测试。这种快速检测可以带来许多医疗上的好处。拟议的简单护理点临床检测系统有可能以较低的成本为更多的患者提供更多的检测。

DESCRIPTION (provided by applicant): Point of care (POC) testing (also referred to as near patient, bed side, or extra laboratory testing) can result in improved clinical outcomes in medical care. These improvements include faster decision making, earlier start of treatment, improved adherence to treatment, reduced incidence of complications, more rapid optimization of treatment, reduced hospital readmission rate, and better patient satisfaction. Additional operational and economic benefits can also accrue. These potential benefits have created a growing market for POC tests that can aid in the diagnosis and treatment of a wide variety of medical diseases and conditions. To achieve effective and accurate POC testing, the assay methodology must be easy to use, provide accurate answers, provide results on a time scale, require handheld or small bench top instrumentation, and require minimal training of assay performers. A limitation to the methodologies currently seeking to meet the needs of POC testing is the cost and complexity of the instruments used, and the training required to correctly perform the assay procedures. To overcome this limitation, Intelligent Optical Systems proposes to extend a simple label- free clinical assay system to a wide range of POC applications, and to later use this same technology to address high throughput screening applications. The estradiol assay developed in Phase I work, which is based on the observation of localized surface plasmon resonance (LSPR) on an array of Ag nanoplates, will be extended to the development of a clinical assay panel for the early diagnosis of ovarian cancer. These panels will simultaneously assay several indicators used for the prognosis of breast cancer, and for fertility treatment. These are medically significant, commercially attractive applications that will allow the basic LSPR assay system to be developed into a commercial product. Designs will be developed for assay chemistries, disposable assay substrates, and a handheld instrument for operation of all assays. The commercialization of these products is expected to lead to further expansions of the assay technology, and as a platform for a wide range of POC testing. The assay system will also be expanded to address high throughput screening applications. Considerable savings in the time and cost of both types of assays is anticipated. PUBLIC HEALTH RELEVANCE: It is now possible to perform many clinical medical tests in a short period of time at the location where patient care is being given. Many medical benefits can be gained from such rapid testing. The proposed simple point of care clinical assay system has the potential of making more tests available to more patients at a lower cost.